These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 21955197)

  • 41. [Feature analysis of IDH1 mutation in oligodendroglial tumors].
    Ren XH; Cui XL; Shang ZM; Lin S
    Zhonghua Yi Xue Za Zhi; 2012 Mar; 92(11):724-6. PubMed ID: 22781348
    [TBL] [Abstract][Full Text] [Related]  

  • 42. From standard treatment to personalized medicine: role of IDH1 mutations in low-grade glioma evolution and treatment.
    Ferroli P; Acerbi F; Finocchiaro G
    World Neurosurg; 2010 Apr; 73(4):234-6. PubMed ID: 20849763
    [No Abstract]   [Full Text] [Related]  

  • 43. IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas.
    Nobusawa S; Watanabe T; Kleihues P; Ohgaki H
    Clin Cancer Res; 2009 Oct; 15(19):6002-7. PubMed ID: 19755387
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Hyperpolarized [1-13C] glutamate: a metabolic imaging biomarker of IDH1 mutational status in glioma.
    Chaumeil MM; Larson PE; Woods SM; Cai L; Eriksson P; Robinson AE; Lupo JM; Vigneron DB; Nelson SJ; Pieper RO; Phillips JJ; Ronen SM
    Cancer Res; 2014 Aug; 74(16):4247-57. PubMed ID: 24876103
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Mutant IDH1 regulates the tumor-associated immune system in gliomas.
    Amankulor NM; Kim Y; Arora S; Kargl J; Szulzewsky F; Hanke M; Margineantu DH; Rao A; Bolouri H; Delrow J; Hockenbery D; Houghton AM; Holland EC
    Genes Dev; 2017 Apr; 31(8):774-786. PubMed ID: 28465358
    [TBL] [Abstract][Full Text] [Related]  

  • 46. NADP+ -dependent IDH1 R132 mutation and its relevance for glioma patient survival.
    Baldewpersad Tewarie NM; Burgers IA; Dawood Y; den Boon HC; den Brok MG; Klunder JH; Koopmans KB; Rademaker E; van den Broek HB; van den Bersselaar SM; Witjes JJ; Van Noorden CJ; Atai NA
    Med Hypotheses; 2013 Jun; 80(6):728-31. PubMed ID: 23541771
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [IDH mutation on glioma].
    Mukasa A
    Gan To Kagaku Ryoho; 2011 Jun; 38(6):937-40. PubMed ID: 21751529
    [No Abstract]   [Full Text] [Related]  

  • 48. A Potent Blood-Brain Barrier-Permeable Mutant IDH1 Inhibitor Suppresses the Growth of Glioblastoma with IDH1 Mutation in a Patient-Derived Orthotopic Xenograft Model.
    Machida Y; Nakagawa M; Matsunaga H; Yamaguchi M; Ogawara Y; Shima Y; Yamagata K; Katsumoto T; Hattori A; Itoh M; Seki T; Nishiya Y; Nakamura K; Suzuki K; Imaoka T; Baba D; Suzuki M; Sampetrean O; Saya H; Ichimura K; Kitabayashi I
    Mol Cancer Ther; 2020 Feb; 19(2):375-383. PubMed ID: 31727689
    [TBL] [Abstract][Full Text] [Related]  

  • 49. IDH1 overexpression induced chemotherapy resistance and IDH1 mutation enhanced chemotherapy sensitivity in Glioma cells in vitro and in vivo.
    Wang JB; Dong DF; Wang MD; Gao K
    Asian Pac J Cancer Prev; 2014; 15(1):427-32. PubMed ID: 24528069
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Glioma cells with the IDH1 mutation modulate metabolic fractional flux through pyruvate carboxylase.
    Izquierdo-Garcia JL; Cai LM; Chaumeil MM; Eriksson P; Robinson AE; Pieper RO; Phillips JJ; Ronen SM
    PLoS One; 2014; 9(9):e108289. PubMed ID: 25243911
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Wild-type isocitrate dehydrogenase under the spotlight in glioblastoma.
    Alzial G; Renoult O; Paris F; Gratas C; Clavreul A; Pecqueur C
    Oncogene; 2022 Jan; 41(5):613-621. PubMed ID: 34764443
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [IDH gene mutation in brain tumors].
    Sonoda Y; Tominaga T
    No Shinkei Geka; 2012 Apr; 40(4):297-306. PubMed ID: 22466228
    [No Abstract]   [Full Text] [Related]  

  • 53. Tailored therapy in diffuse gliomas: using molecular classifiers to optimize clinical management.
    Taylor JW; Chi AS; Cahill DP
    Oncology (Williston Park); 2013 Jun; 27(6):504-14. PubMed ID: 23909061
    [TBL] [Abstract][Full Text] [Related]  

  • 54. IDH mutation in glioma: new insights and promises for the future.
    Turkalp Z; Karamchandani J; Das S
    JAMA Neurol; 2014 Oct; 71(10):1319-25. PubMed ID: 25155243
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Oncogenic KRAS hotspot mutations are rare in IDH-mutant gliomas.
    Schittenhelm J; Krischker N; Gepfner-Tuma I; Behling F; Noell S; Eckert F; Biskup S; Tabatabai G
    Brain Pathol; 2019 May; 29(3):321-324. PubMed ID: 30676672
    [No Abstract]   [Full Text] [Related]  

  • 56. Mutant IDH1 inhibits PI3K/Akt signaling in human glioma.
    Birner P; Pusch S; Christov C; Mihaylova S; Toumangelova-Uzeir K; Natchev S; Schoppmann SF; Tchorbanov A; Streubel B; Tuettenberg J; Guentchev M
    Cancer; 2014 Aug; 120(16):2440-7. PubMed ID: 24771584
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Glioma IDH1 mutation patterns off the beaten track.
    Pusch S; Sahm F; Meyer J; Mittelbronn M; Hartmann C; von Deimling A
    Neuropathol Appl Neurobiol; 2011 Jun; 37(4):428-30. PubMed ID: 20874727
    [No Abstract]   [Full Text] [Related]  

  • 58. Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha.
    Zhao S; Lin Y; Xu W; Jiang W; Zha Z; Wang P; Yu W; Li Z; Gong L; Peng Y; Ding J; Lei Q; Guan KL; Xiong Y
    Science; 2009 Apr; 324(5924):261-5. PubMed ID: 19359588
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Energy Metabolism in
    van Noorden CJF; Hira VVV; van Dijck AJ; Novak M; Breznik B; Molenaar RJ
    Cells; 2021 Mar; 10(3):. PubMed ID: 33810170
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A map of the altered glioma metabolism.
    Deshmukh R; Allega MF; Tardito S
    Trends Mol Med; 2021 Nov; 27(11):1045-1059. PubMed ID: 34489164
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.